Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989;27 Suppl 1(Suppl 1):79S-85S.
doi: 10.1111/j.1365-2125.1989.tb03466.x.

The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients

Affiliations

The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients

E Ben-Menachem et al. Br J Clin Pharmacol. 1989.

Abstract

1. Vigabatrin, 50 mg kg-1, was administered orally as add-on therapy to 11 patients with drug-resistant complex partial epilepsy as a single dose, then once every third day for 2 months, every other day for 2 months and daily for 1 month. 2. Lumbar punctures were carried out prior to treatment and at the end of each dosage regimen and cerebrospinal fluid (CSF) evaluated for concentrations of free and total GABA, homocarnosine (GABA-histidine dipeptide), homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA) and vigabatrin. 3. Each regimen resulted in significant increases in CSF concentrations of free and total GABA and homocarnosine compared with the immediately preceding regimen. 4. CSF concentrations of HVA significantly increased after a single vigabatrin dose but returned to pre-treatment levels with subsequent dosing schedules. In contrast, 5-HIAA concentrations also increased with the single dose but were significantly decreased, compared with pre-treatment values, following alternate day and daily vigabatrin administration. 5. Seizure frequency progressively decreased with decreasing dosing interval. Daily vigabatrin administration was associated with greater than 50% decrease in seizures in 8 of the 10 patients treated.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Epilepsy Res. 1988 Mar-Apr;2(2):96-101 - PubMed
    1. Arch Neurol. 1987 Sep;44(9):907-10 - PubMed
    1. Eur J Pharmacol. 1977 Oct 15;45(4):319-28 - PubMed
    1. J Neurochem. 1977 Nov;29(5):797-802 - PubMed
    1. Lancet. 1978 Aug 5;2(8084):304-6 - PubMed